Malignant hyperthermia;Maligne hyperthermie. Allgemeine, klinische und experimentelle aspekte

Anaesthesist

Volumn 51, Issue 4, 2002, Pages 328-345

  Steinfath, M ^a   Wappler, F ^b   Scholz, J ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIHYDROPYRIDINE RECEPTOR; ANTIARRHYTHMIC AGENT; DANTROLENE; DESFLURANE; ENFLURANE; HALOTHANE; INHALATION ANESTHETIC AGENT; INOSITOL PHOSPHATE; INOSITOL TRISPHOSPHATE; ISOFLURANE; KETAMINE; META CRESOL; MUSCLE RELAXANT AGENT; PSYCHOTROPIC AGENT; RYANODINE RECEPTOR; SEROTONIN 2 RECEPTOR; SEROTONIN RECEPTOR; SEVOFLURANE;

BODY TEMPERATURE; CALCIUM HOMEOSTASIS; CHROMOSOMAL LOCALIZATION; CLINICAL FEATURE; DISEASE COURSE; DUCHENNE MUSCULAR DYSTROPHY; GENE MUTATION; GERMANY; HUMAN; HYPERCAPNIA; HYPERVENTILATION; INCIDENCE; INJECTION; LABORATORY TEST; MALIGNANT HYPERTHERMIA; NEUROLEPTIC MALIGNANT SYNDROME; OSTEOGENESIS IMPERFECTA; PATHOPHYSIOLOGY; POSTOPERATIVE PERIOD; PREMEDICATION; PREOPERATIVE PERIOD; PROGNOSIS; RATING SCALE; REVIEW; SECOND MESSENGER; STRESS; SYMPTOMATOLOGY; TACHYCARDIA; TACHYPNEA;

ANIMALS; HUMANS; MALIGNANT HYPERTHERMIA; SECOND MESSENGER SYSTEMS;

EID: 0036234116     PISSN: 00032417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00101-002-0314-9     Document Type: Review

References (50)

1. The genetics of malignant hyperthermia
2. Inositol trisphosphate and calcium signalling
3. Screening of the ryanodine receptor gene in 105 malignant hyperthermia families: Novel mutations and concordance with the in vitro contracture test
4. Intracellular calcium homeostasis in human primary muscle cells from malignant hyperthermia-susceptible and normal individuals
5. Discordance, in a malignant hyperthermia pedigree, between in vitro contracture-test phenotype and haplotypes for the MHSI region on chromosome 19q12-13.2, comprising the C1840T transition in the RYRI gene
6. Malignant hyperthermia during sevoflurane administration
7. Halothane-induced muscle contracture as a cause of hyperpyrexia
8. A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility
9. Abnormal ryanodine receptor channels in malignant hyperthermia
10. Identification of a mutation in porcine ryanodine receptor associated with malignant hyerthermia
11. Suxamethonium chloride and malignant hyperthermia
12. A substitution of cysteine for arginine 614 in the ryanodine receptor is potentially causative of human malignant hyperthermia
13. Control of malignant hyperpyrexia syndrome in MHS swine by dantrolene sodium
14. Die regionale verbreitung der maligne hyperthermie veranlagung in Deutschland: Stand 1997
15. Ryanodine contracture: A potentially specific in vitro diagnostic test for malignant hyperthermia
16. False-negative results with muscle caffeine halothane contracture testing for malignant hyperthermia
17. Metabolic error of muscle metabolism after recovery from malignant hyperthermia
18. Purification and reconstitution of the calcium release channel from skeletal muscle
19. A clinical grading scale to predict malignant hyperthermia susceptibility
20. Pharmacodynamic effects of serotonin (5-HT) receptor ligands in pigs: Stimulation of 5-HT2 receptors induces malignant hyperthermia
21. Malignant hyperthermia
22. Ryanodine receptor gene is a candidate for predisposition to malignant hyperthermia
23. Maligne hyperthermie in Österreich. I. Epidemiology und klinik
24. Localization of the malignant hyperthermia susceptibility locus to human chromosome 19q12-13.2
25. Ryanodine receptor mutations in malignant hyperthermia and central core disease
26. Früherkennung einer malignen hyperthermie durch capnometrie
27. 2+ release channel and their regulation by endogenous effectors
28. Putative receptor for inositol 1,4,5-trisphosphate similar to ryanodine receptor
29. Abnormality in calcium release from skeletal sarcoplasmic reticulum of pigs susceptible to malignant hyperthermia
30. Incidence of malignant hyperthermia in Denmark
31. In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: Results of testing patients surviving fulminant MH and unrelated low-risk subjects
32. Identification of dantrolene binding sites in porcine skeletal muscle sarcoplasmic reticulum
33. Mutations in the ryanodine receptor gene in central core disease and malignant hyperthermia
34. Effects of three different types of management on the elimination kinetics of volatile anaesthetics
35. Evaluierung von maligne hyperthermie-episoden mit der Clinical Grading Scale
36. Maligne hyperthermie heute
37. North american malignant hyperthermia population: Screening of the ryanodine receptor gene and identification of novel mutations
38. Welche bedeutung haben genotyp-veränderungen in der diagnostik der malignen hyperthermia?
39. Die maligne hyperthermie
40. Malignant hyperthermia
41. Effekte von serotonin-2-rezeptoragonisten auf skelettmuskelpräparate von patienten mit disposition zu maligner hyperthermie
42. In vitro-diagnosis of malignant hyperthermia susceptibility with ryanodine-induced contractures in human skeletal muscles
43. 4-Chloro-m-Cresol induziert kontrakturen an skelettmuskelpräparaten von patienten mit disposition zu maligner hyperthermie
44. Evidence for susceptibility to malignant hyperthermia in patients with exercise-induced rhabdomyolysis
45. Malignant hyperthermia - Diagnostic dilemma: False-negative contracture responses with halothane and caffeine alone
46. Desflurane is a trigger of malignant hyperthermia in susceptible swine
47. Delayed onset of malignant hyperthermia induced by isoflurane and desflurane compared with halothane in susceptible swine
48. Malignant hyperthermia: A human stress syndrome?
49. 2+ release
50. 2+ release channel (ryanodine receptor) of skeletal muscle sarcoplasmic reticulum